drugset / Trial / NCT00206141

Seroquel in Bipolar Depression Versus Lithium

NCT00206141

Phase 3 Completed 672 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to 52 with quetiapine fumarate (Seroquel) compared to placebo.

Timeline

Start
2005-08
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 300 mg
Subject Quetiapine Small molecule 600 mg

Indications